ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum

When we have to choose between two potent P2Y12 receptor inhibitors for a patient undergoing ACS with a planned invasive strategy, kidney function should not interfere in this decision. 

The main findings of this study were that prasugrel has lower risk of all cause death, MI or stroke, and also had a similar risk of bleeding compared against ticagrelor. These findings were consistent with those of low and intermediate risk patients or high glomerular filtration. 

These findings were presented during the ESC 2021 scientific sessions and were simultaneously published in JACC: Cardiovascular Interventions.

Patients with altered kidney function are challenging for multiple reasons: on the one hand, they present higher ischemic risk and on the one hand, a higher risk of bleeding, given drug pharmacokinetics. 

For this analysis, the authors divided 4,012 participants according to glomerular filtration into 3 groups: low (<60 mL/min/1.73; m2; 760 patients), intermediate (60 to 90 mL/min/1.73 m2; 1968 patients) and high (>90 mL/min/1.73 m2; 1284 patients).

As expected, the worse the glomerular filtration, the bigger the number of events, both ischemic and hemorrhagic.  

However, this did not affect the relative efficacy of prasugrel. Moreover, its biggest advantage was in patients with worse glomerular filtration. 


Read also: ESC 2021 | TOMAHAWK: Angiography After Resuscitated Patients from Out-Of-Hospital Cardiac Arrest with No ST Elevation.


Specifically, in this last subgroup, the rate of all cause death, MI or stroke was significantly higher in patients receiving ticagrelor vs prasugrel (20.5% vs 14.7%; HR 1.47; CI 95% 1.04 to 2.08), with no cost in bleeding BARC 3-5 (10.4% vs 8.4%; HR 1.24; CI 95% 0.73-2.09).

After a few years of absolute dominion of ticagrelor, several studies have slowly brought back prasugrel and clopidogrel to the current clinical arena.  

Original Title: Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate. 

Reference: Wöhrle J. J Am Coll Cardiol Intv. 2021; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Left or Right Transradial Approach? Comparing Radiation Exposure in Coronary Procedures

Radiation exposure during percutaneous procedures is a problem both for patients and operators. The transradial is currently the preferred approach, vs. femoral; however, whether...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....